These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 5081591)

  • 1. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
    Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
    Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of route of administration on antileukemic activity of cyclocytidine.
    Hoshi A; Kanzawa F; Kuretani K
    Gan; 1972 Apr; 63(2):279-80. PubMed ID: 5070242
    [No Abstract]   [Full Text] [Related]  

  • 3. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210.
    Vadlamudi S; Goldin A
    Cancer Chemother Rep; 1971 Dec; 55(5):547-55. PubMed ID: 5159846
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of route of administration on antileukemic activity of cytosine arabinoside (NSC-63878) in advanced leukemia L1210 in mice.
    Kline I; Tyrer DD; Gang M; Venditti JM; Goldin A
    Cancer Chemother Rep; 1968 Apr; 52(3):399-404. PubMed ID: 5670722
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
    Kline I; Woodman RJ; Gang M; Sirica A; Venditti JM; Goldin A
    Cancer Chemother Rep; 1972 Jun; 56(3):327-34. PubMed ID: 19051491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.
    Grem JL; Plowman J; Rubinstein L; Hawkins MJ; Harrison SD
    Leuk Res; 1991; 15(4):229-36. PubMed ID: 2030604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
    Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM
    Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
    [No Abstract]   [Full Text] [Related]  

  • 10. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878).
    Shackney SE
    Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022
    [No Abstract]   [Full Text] [Related]  

  • 11. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
    Hashida M; Kojima T; Muranishi S; Sezaki H
    Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on the relationship between therapeutic schedule and antitumor effect of etoposide and cytosine arabinoside in murine L1210 leukemia].
    Ooi K; Ohkubo T; Kawasaki H; Sakurai M
    Yakugaku Zasshi; 1989 Nov; 109(11):865-8. PubMed ID: 2614669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
    Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
    Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antileukemic activity of liposome forms of cytosine arabinoside and cyclocytidine].
    Reshchikov VP; Afonin NI; Ermakov LN; Fertukova NM; Oksinoĭd OE
    Gematol Transfuziol; 1984; 29(5):49-51. PubMed ID: 6203808
    [No Abstract]   [Full Text] [Related]  

  • 15. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
    Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice.
    Neil GL; Wiley PF; Manak RC; Moxley TE
    Cancer Res; 1970 Apr; 30(4):1047-54. PubMed ID: 5504347
    [No Abstract]   [Full Text] [Related]  

  • 17. Antitumor activity of cyclocytidine in a variety of tumors.
    Hoshi A; Kanzawa F; Kuretani K
    Gan; 1972 Jun; 63(3):353-60. PubMed ID: 5072834
    [No Abstract]   [Full Text] [Related]  

  • 18. [The mechanism of synergistic interaction between etoposide and cytarabine].
    Ooi K
    Yakugaku Zasshi; 2002 Jul; 122(7):471-80. PubMed ID: 12136643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC; Trader MW; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.